Actelion Ltd. entered potentially it's biggest ever deal, a strategic collaboration in the area of orexin antagonists with GlaxoSmithKline plc that could be worth up to CHF3.3 billion (US$3.2 billion) in up-front, development and sales-related milestones. (BioWorld International)

Actelion Ltd. entered potentially it's biggest ever deal, a strategic collaboration in the area of orexin antagonists with GlaxoSmithKline plc that could be worth up to CHF3.3 billion (US$3.2 billion) in up-front, development and sales-related milestones. (BioWorld Today)

Max Planck Innovation GmbH, the technology transfer arm of Germany's Max Planck Society, has spun out a new subsidiary, the Lead Discovery Center GmbH (LDC), to take forward innovative, early stage projects that are as yet unready for commercial out-licensing deals. (BioWorld International)